Skinos Unveils Exciplex: A Revolutionary FDA-Approved Device for Autoimmune Skin Disease Treatment

▴ Device for Autoimmune Skin Disease Treatment
By offering a quick, effective, and user-friendly solution, the Exciplex helps patients manage their conditions more effectively, reducing the psychological burden and improving overall quality of life.

In a major advancement for the treatment of autoimmune skin diseases, Skinos, a leading provider of aesthetic services, has introduced its latest innovation, the Exciplex. This handheld monochromatic Excimer Light platform has received approval from the US Food and Drug Administration (FDA) and represents a significant leap forward in dermatological care.

The Exciplex device emits light at a wavelength of 308 nanometers (nm), which is specifically optimized for treating chronic autoimmune skin conditions. This precise wavelength has been proven effective in managing a variety of skin issues, including:

- Vitiligo
- Psoriasis
- Alopecia Areata
- Mycosis Fungoides
- Atopic Dermatitis

Dr. Shruti Gupta, the Medical Director and Dermatologist at Skinos, emphasized the clinical efficiency of the Exciplex, noting its widespread recognition among dermatologists globally.


One of the standout features of the Exciplex is its ability to provide quick and effective treatments, which is particularly beneficial for conditions like Vitiligo and Psoriasis. These conditions often lead to social withdrawal and stigma, causing significant stress and anxiety for those affected. Excimer Light Therapy, such as that offered by the Exciplex, plays a crucial role in addressing these visible skin conditions, helping to improve patients' quality of life.

The Exciplex offers numerous advantages, making it a valuable tool for both patients and healthcare providers:

1. Compact and Portable Design: As the smallest Monochromatic Excimer Light platform available, the Exciplex is ideal for treating localized autoimmune skin conditions. Its lightweight and portable design make it easy to use in various clinical settings.

2. Versatile Treatment Capabilities: With a spot size of 25 square centimeters, the device can efficiently target large areas of the skin. It also includes reduction tips to accommodate smaller lesions, ensuring precise treatment.

3. User-Friendly Interface: The Exciplex features an intuitive touchscreen interface, simplifying the treatment process for clinicians.

4. Cost-Effective and Environmentally Friendly: Unlike many other treatment devices, the Exciplex does not require any consumables, making it a cost-effective option for ongoing treatments. Its lack of consumables also makes it an environmentally friendly choice.

Dr. Gupta emphasized the safety and effectiveness of the Exciplex, citing numerous clinical studies that support its efficacy in treating autoimmune skin conditions. The FDA approval further highlights the device's reliability and safety for both patients and clinicians.

The introduction of the Exciplex by Skinos is poised to transform the treatment landscape for autoimmune skin diseases. By offering a quick, effective, and user-friendly solution, the Exciplex helps patients manage their conditions more effectively, reducing the psychological burden and improving overall quality of life.

The Exciplex device by Skinos represents a significant advancement in the treatment of autoimmune skin diseases. With its FDA approval, this handheld Excimer Light platform offers a safe, effective, and environmentally friendly option for managing chronic skin conditions like Vitiligo, Psoriasis, and Atopic Dermatitis. The Exciplex not only provides quick and effective treatments but also offers numerous benefits for both patients and healthcare providers, making it a valuable addition to modern dermatological care.

Tags : #

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

The Future of Indian MedTech Exports: Can India Compete With Global Leaders?September 17, 2026
Robotic-Assisted Procedures Beyond Surgery: Where Is Automation Going Next in Healthcare?September 17, 2026
Tracky launches 16D, India's first 16-day continuous glucose monitoring system (CGM)September 16, 2026
Why Local Medical Device Manufacturing Matters for Indian HealthcareSeptember 16, 2026
Next-Generation Surgical Robots Entering the Indian Market: What It Means for Patients and ProvidersSeptember 16, 2026
ShardaCare - Healthcity Marks World Sepsis Day with Training for Over 50 NursesSeptember 15, 2026
From Empowerment to Ownership: Upasana Kamineni Konidela Calls for a BRICS Women’s Economic CorridorSeptember 15, 2026
WORLD HEART DAY 2026: Don't Miss a Beat: The Heart Attacks That Never Had to HappenSeptember 15, 2026
BL Agro Announces Investment of ₹1,500 Crore In Its Biotech-Arm Leads Genetics To Build An Integrated Dairy and Genetics EcosystemSeptember 15, 2026
Can You Have PMOS With Regular Periods? What Women Often Get WrongSeptember 15, 2026
Hospital Data Breaches in India: What Every Patient Needs to Know Right NowSeptember 15, 2026
Cybersecurity of ICUs: Protecting Connected Critical-Care Systems in Indian HospitalsSeptember 15, 2026
Fortis Hospital, Shalimar Bagh Becomes Delhi NCR’s First Multi-speciality Hospital to Launch Rezūm™ Water Vapor Therapy for Enlarged ProstateSeptember 14, 2026
Dr. Reddy's Laboratories Launches Nationwide Educational Initiative to Strengthen India's Obesity Care WorkforceSeptember 14, 2026
IIM Bodh Gaya Hosts Convergence 3.0: The Next Frontier of Healthcare SectorSeptember 14, 2026
A Practical Guide to Fibre: How Indian Adults Can Add More Without Digestive DiscomfortSeptember 12, 2026
Understanding Heart Palpitations: Common Triggers, Helpful Records, and Warning SignsSeptember 12, 2026
The Fourth Trimester: Why Healthcare Often Stops Too Early After DeliverySeptember 12, 2026
Postpartum Mental Health: The Healthcare Gap Nobody Talks About EnoughSeptember 12, 2026
Fortis Escorts Faridabad Launches Region’s First Dedicated ‘Fever Clinic’ for Early Diagnosis and Timely TreatmentSeptember 11, 2026